Characteristics of Cutaneous Lupus Erythematosus Patients in Dermatology and Venereology Outpatient Clinic
Downloads
Background: Cutaneous lupus erythematosus (CLE) is a specific skin manifestation of lupus erythematosus. This condition can be accompanied by systemic involvement that affect patient therapy and prognosis. The characteristics of CLE patients in Indonesia have not been widely reported. This study aims to determine the prevalence and characteristics of CLE patients at Dermatology and Venereology Outpatient Clinic of Allergy and Immunology Division at Ngoerah Hospital. Methods: This research used descriptive analysis with a cross-sectional design and total sampling method. Result: The total number of patients was 34, with prevalence of 6.7 cases per 1,000 patients. The majority of patients were female (85.3%), Balinese ethnicity (70.6%), unemployed (53%), with a high school/vocational high school education (56%), and risk factors of sun exposure (80.0%). Most patients had no family history of Lupus erythematosus (LE) (65.7%). The most frequent skin manifestation was chronic type CLE (28.6%). Based on The European League Against Rheumatism/American College of Rheumatology (EULAR/ACR) score, 27 patients (77.1%) met Systemic lupus erythematosus (SLE) criteria. Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) activity, damage, and Mexican Systemic Lupus Erythematosus Disease Activity (MEX-SLEDAI) scores were 3.35±4.52, 0.88±1.96, and 7.5±5.09. Systemic therapy included methylprednisolone (47%) and hydroxychloroquine (35.2%), topical treatment included high to very high-potency steroids (67.6%), and sunscreen (14.7%). Response therapy was generally good in 68.6% of patients. Conclusion: The most common type of CLE is chronic cutaneous lupus erythematosus. Most patients improved, with the majority using systemic methylprednisolone and topical high-potency corticosteroids. Oral treatment responses tend to be good.
Fijałkowska A, Kądziela M, Żebrowska A. The Spectrum of Cutaneous Manifestations in Lupus Erythematosus: A Comprehensive Review. J Clin Med 2024;13.
Elmgren J, Nyberg F. Clinical aspects of cutaneous lupus erythematosus. Front Med (Lausanne) 2023;9.
Cooper EE, Pisano CE, Shapiro SC. Cutaneous Manifestations of “lupus”: Systemic Lupus Erythematosus and beyond. Int J Rheumatol 2021;2021.
Guleva D, Balabanova M, Miteva L, et al. Histology of Skin Alterations in Lupus Erythematosus. Acta Medica Bulgarica 2022; 49:28–32.
Bitar C, Menge TD, Chan MP. Cutaneous manifestations of lupus erythematosus: a practical clinicopathological review for pathologists. Histopathology 2022; 80:233–50.
Drenkard C, Barbour KE, Greenlund KJ, et al. The Burden of Living with Cutaneous Lupus Erythematosus. Front Med (Lausanne) 2022;9.
Walker AM, Lu G, Clifton SC, et al. Influence of Socio-Demographic Factors in Patients with Cutaneous Lupus Erythematosus. Front Med (Lausanne) 2022;9.
Hadisuwarno W, Rahmawati LD. An Indonesian female with severe cutaneous lupus erythematosus: A case report and literature review. Int J Surg Case Rep 2023;107.
Sutedja E, Widjaya MRH, Dharmadji HP, et al. Lupus Erythematosus Profundus with Multiple Overlying Cutaneous Ulcerations: A Rare Case. Clin Cosmet Investig Dermatol 2023; 16:2721–6.
Anderson SR, Hynan LS, Chong BF. Late-onset cutaneous lupus erythematosus patients have distinctive clinical features and demographics versus early-onset patients. Lupus 2022; 31:1523–8.
Lopes Almeida Gomes L, Werth AJ, Thomas P, et al. The impact of hormones in autoimmune cutaneous diseases. Journal of Dermatological Treatment 2024;35.
Rafael-vidal C, Altabás I, Pérez N, et al. Calcineurin and systemic lupus erythematosus: The rationale for using calcineurin inhibitors in the treatment of lupus nephritis. Int J Mol Sci 2021; 22:1–14.
Nayak D, Behera B, Dalei SR, et al. Changing Trends of Cutaneous Lupus Erythematosus (CLE) in a Tertiary Care Hospital in Northern Odisha, India. Cureus 2023.
Keum H, Brown LS, Chong BF. Black patients with cutaneous lupus are associated with a positive family history of cutaneous lupus and systemic lupus. Lupus Sci Med 2022;9.
Klein B, Kunz M. Current concepts of photosensitivity in cutaneous lupus erythematosus. Front Med (Lausanne) 2022;9.
Mowla MR, Barua DP, Zaman S, et al. Clinicopathological characteristics of cutaneous lupus erythematosus patients in Bangladesh. Postepy Dermatol Alergol 2022; 39:782–7.
Milne M, Sims C, Anderson DR, et al. A Rare Manifestation of a Rare Disease: The Importance of Thinking Outside the Box in a Patient with Complex Dermatomyositis. Arthritis Care Res (Hoboken) 2022; 74:1943–9.
Putri JG, Wisan AB. Efek Samping Terapi Kortikosteroid Sistemik Jangka Panjang pada Pasien Lupus Erimatosus Sistemik dan Tatalaksana Dermatologi. CDK-283 2020;47(2):127-9.
Alharbi S. Gastrointestinal Manifestations in Patients with Systemic Lupus Erythematosus. Open Access Rheumatol 2022; 14:243–53.
Stojan G, Li J, Wittmaack A, et al. Cachexia in Systemic Lupus Erythematosus: Risk Factors and Relation to Disease Activity and Damage. Arthritis Care Res (Hoboken) 2021; 73:1577–82.
Żychowska M, Reich A. Dermoscopic Features of Acute, Subacute, Chronic and Intermittent Subtypes of Cutaneous Lupus Erythematosus in Caucasians. J Clin Med 2022;11.
Abozaid HSM, Hefny HM, Abualfadl EM, et al. Negative ANA-IIF in SLE patients: what is beyond? Clin Rheumatol 2023; 42:1819–26.
Muñoz-Grajales C, Yilmaz EB, Svenungsson E, et al. Systemic lupus erythematosus and damage: What has changed over the past 20 years? Best Pract Res Clin Rheumatol 2023;37.
Kim CS, Han K Do, Jung JH, et al. Incidence and risk factors for osteoporotic fractures in patients with systemic lupus erythematosus versus matched controls. Korean Journal of Internal Medicine 2021; 36:154–63.
Lai E-L, Huang W-N, Chen H-H, et al. Degraded microarchitecture by low trabecular bone score is associated with prevalent vertebral fractures in patients with systemic lupus erythematosus. Arch Osteoporos 2020; 15: 54.
Morand EF, Fernandez-Ruiz R, Blazer A, et al. Advances in the management of systemic lupus erythematosus. BMJ 2023.
Chakka S, Krain RL, Concha JSS, et al. The CLASI, a validated tool for the evaluation of skin disease in lupus erythematosus: a narrative review. Ann Transl Med 2021; 9:431–431.
Alowaid SK, Alqahtani J, Alarfaj OA, et al. Sunscreen use among lupus erythematosus patients in Saudi Arabia. Med Sci 2022; 26:01–9.
Wallace DJ, Hahn BH, editors. Dubois’ Lupus Erythematosus and Related Syndromes. 9th ed. Philadelphia: Elsevier; 2018.
Tier HL, Balogh EA, Bashyam AM, et al. Tolerability of and Adherence to Topical Treatments in Atopic Dermatitis: A Narrative Review. Dermatol Ther (Heidelb) 2021; 11:415–31.
Copyright (c) 2025 Berkala Ilmu Kesehatan Kulit dan Kelamin

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
- Copyright of the article is transferred to the journal, by the knowledge of the author, whilst the moral right of the publication belongs to the author.
- The legal formal aspect of journal publication accessibility refers to Creative Commons Atribusi-Non Commercial-Share alike (CC BY-NC-SA), (https://creativecommons.org/licenses/by-nc-sa/4.0/)
- The articles published in the journal are open access and can be used for non-commercial purposes. Other than the aims mentioned above, the editorial board is not responsible for copyright violation
The manuscript authentic and copyright statement submission can be downloaded ON THIS FORM.















